JASCAYD (Nerandomilast) Patent Expiration, LOE Window & CMS Spending

JASCAYD (Nerandomilast) by Boehringer Ingelheim: FDA Orange Book core substance LOE 2032-08-23 (last listed 2038-10-22), 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $16,220 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBoehringer Ingelheim
FDA Application & PathwayN218764 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2032-08-23
Last Listed Patent or Exclusivity Date2038-10-22
Orange Book Patents (*PED Extensions)14 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($16,220 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Boehringer Ingelheim across sibling Meru public-data platforms.